StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Equities researchers at StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Down 11.1 %

Shares of NASDAQ:TNXP opened at $0.26 on Thursday. The company has a market cap of $47.84 million, a PE ratio of 0.00 and a beta of 2.02. The firm has a 50 day simple moving average of $0.25 and a 200 day simple moving average of $0.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $12.48.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, research analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.